Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00543426
Other study ID # 06DZ19728
Secondary ID
Status Completed
Phase Phase 4
First received October 12, 2007
Last updated March 6, 2013
Start date September 2007
Est. completion date June 2009

Study information

Verified date June 2009
Source Shanghai University of Traditional Chinese Medicine
Contact n/a
Is FDA regulated No
Health authority China: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

The primary purpose of the trial is adopted Fuzheng Huayu tablets against posthepatitic cirrhosis, and to build a standard evaluation system for efficacy of traditional Chinese medicine (TCM).

The second purpose is according to the international clinical guideline and the specialty of TCM to build a standard clinical trial regulation for traditional Chinese medicine.


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date June 2009
Est. primary completion date May 2009
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Clinical diagnosis of B Post hepatitic cirrhosis.

- Male or female patients between 18~65 years old.

- Written informed consent.

Exclusion Criteria:

- Child-Pugh C above 12, or ALT > 2×ULN, TBiL > 2×ULN, or combined with hepatic encephacopathy, Obstinate ascites, bleeding tendency, hepato-renal syndrome, or primary liver cancer.

- Combined with severe heart, gallbladder, kidney, endocrine system, hemopoietic system or nervous system disease.

- Deformed man by the law.

- Pregnancy or breast feeding women, or unwilling to have contraception.

- Irritability body constitution, or irritability of the Fuzheng Huayu Capsules.

- Enter other trials lately one month.

- Other cause of cirrhosis.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Fuzheng Huayu Tablets
Tablet,three times a day,four tablets one time
sham Fuzheng Huayu Tablets (placebo)
Tablet, three times a day, four tablets one time

Locations

Country Name City State
China Shuguang Hospital Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Shanghai University of Traditional Chinese Medicine

Country where clinical trial is conducted

China, 

References & Publications (3)

Liu P, Hu YY, Liu C, Xu LM, Liu CH, Sun KW, Hu DC, Yin YK, Zhou XQ, Wan MB, Cai X, Zhang ZQ, Ye J, Tang BZ, He J. [Multicenter clinical study about the action of Fuzheng Huayu Capsule against liver fibrosis with chronic hepatitis B]. Zhong Xi Yi Jie He Xue Bao. 2003 Jul;1(2):89-98, 102. Chinese. — View Citation

Zhang Q, Zhang WT, Wei JJ, Wang XB, Liu P. [Combined use of factor analysis and cluster analysis in classification of traditional Chinese medical syndromes in patients with posthepatitic cirrhosis]. Zhong Xi Yi Jie He Xue Bao. 2005 Jan;3(1):14-8. Chinese. — View Citation

Zhao CQ, Wu YQ, Xu LM. [Curative effects of Fuzheng Huayu capsules on hepatic fibrosis and the functional mechanisms: a review]. Zhong Xi Yi Jie He Xue Bao. 2006 Sep;4(5):467-72. Review. Chinese. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary the value of Child-Pugh and symptoms scale for Posthepatitic Cirrhosis six months Yes
Secondary hepatic function; blood test; blood ammonia and blood sugar determination six months Yes